Abstract

Background: Many researches show risk factors of cardiac disease in individuals suffering from chronic kidney disease (CKD). In CKD patients who are candid CABG, there are great concerns about acute kidney injury. Iincrease in serum Creatinine is associated with increase in morbidity and mortality in CAGB patients. Therefore, purpose of this study is investigating serum creatinine variation and GFR after oral NAC injection in CKD patients who are candid for CABG. Material and Method: 50 patients candid for CAGB were selected in blind design randomized, clinical trial in Golstan and Imam' hospitals in Ahvaz during 2010-2011. All patients had nephropathy type 2 based on kidney fund classification and had diagnostic criteria for chronic kidney diseases or it lasts for three months (GFR<90, Cr>1.5).Intervention group received 600mg oral NAC twice a day from one day before surgery to 5 days after surgery through esophagus catheter and control group received distilled water with same amount and volume. Finally the serum creatinine, GFR and some other factors were measured. Results: there is a significant difference in serum creatinine (P=0.002), GFR (P=0.002) and BUN (P=0.034) between control and intervention groups after 5days. Conclusion: Results of this study and its comparison with other studies showed great disagreement about effect of NAC on serum creatinine but considering lack of side effects or severe changes in serum creatinine in NAC receiving patients, it can be used as a safe drug.